Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: Results from 87 patients treated by the polish myeloma group

View Full Paper
Ask AI
Bookmark
Share

Authors

JKJacek KrzanowskiŁSŁukasz SzukalskiMOMagdalena Olszewska‐Szopa

Discussion

Loading...

Member takes

Overview

Retrospective study reports 77.3% response rate in 87 relapsed myeloma patients, suggesting teclistamab is effective and safe.

Key Points

  • This study aims to evaluate the efficacy and safety of teclistamab in patients with relapsed or refractory multiple myeloma.
  • Conducted as a multicenter retrospective study in 16 Polish hematology/oncology centers.
  • Included patients who initiated teclistamab treatment between August 2023 and March 2025.
  • Responses assessed using International Myeloma Working Group consensus criteria.
  • Safety evaluated through adverse events grading based on CTCAE v5.0.
  • Among 75 evaluable patients, the overall response rate was 77.3%.
  • Median progression-free survival was 13 months, while overall survival was 33 months.
  • Infections were the most common adverse events, with 51.7% reporting respiratory tract infections.

Cite This Study

Krzanowski et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d196https://doi.org/10.1182/blood-2025-5838
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of teclistamab in triple-exposed relapsed/refractory multiple myeloma: Brazilian single-center experience2025
  2. 2Real-World Efficacy and Safety of Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma: Nationwide Retrospective Analysis of the Named Patient Program in Korea2025 · 3 citations
  3. 3Teclisito: Low-intensity teclistamab in the outpatient setting for Relapsed/Refractory multiple myeloma2025
  4. 4Low-dose teclistamab in newly diagnosed multiple myeloma patients2025 · 1 citations
  5. 5Real-world analysis of infection timing and burden in multiple myeloma patients treated with teclistamab2025